[go: up one dir, main page]

GB202312055D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB202312055D0
GB202312055D0 GBGB2312055.3A GB202312055A GB202312055D0 GB 202312055 D0 GB202312055 D0 GB 202312055D0 GB 202312055 A GB202312055 A GB 202312055A GB 202312055 D0 GB202312055 D0 GB 202312055D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2312055.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Irl 790ab
Original Assignee
Irl 790 AB
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irl 790 AB, Ipsen Biopharm Ltd filed Critical Irl 790 AB
Priority to GBGB2312055.3A priority Critical patent/GB202312055D0/en
Publication of GB202312055D0 publication Critical patent/GB202312055D0/en
Priority to PCT/EP2024/072281 priority patent/WO2025032103A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
GBGB2312055.3A 2023-08-07 2023-08-07 Pharmaceutical compositions Ceased GB202312055D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2312055.3A GB202312055D0 (en) 2023-08-07 2023-08-07 Pharmaceutical compositions
PCT/EP2024/072281 WO2025032103A1 (en) 2023-08-07 2024-08-06 Pharmaceutical compositions comprising a tartrate salt of n-[2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2312055.3A GB202312055D0 (en) 2023-08-07 2023-08-07 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB202312055D0 true GB202312055D0 (en) 2023-09-20

Family

ID=88017018

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2312055.3A Ceased GB202312055D0 (en) 2023-08-07 2023-08-07 Pharmaceutical compositions

Country Status (2)

Country Link
GB (1) GB202312055D0 (en)
WO (1) WO2025032103A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566634T3 (en) 2011-04-19 2016-04-14 Integrative Research Laboratories Sweden Ab New modulators of glutamatergic neurotransmission mediated by NMDA receptors and cortical dopaminergic
EP3976581B1 (en) * 2019-05-24 2023-11-22 Irl 790 AB Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine
US20220168242A1 (en) 2020-11-10 2022-06-02 Susanna Holm Waters Pharmaceutically acceptable salts of mesdopetam and uses thereof

Also Published As

Publication number Publication date
WO2025032103A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
GB202019241D0 (en) Pharmaceutical composition
IL300090A (en) Pharmaceutical compositions comprising venglustat
IL304290A (en) Pharmaceutical composition
IL314046A (en) Ribociclib pharmaceutical compositions
GB202019335D0 (en) Pharmaceutical compositions
GB202208464D0 (en) Pharmaceutical composition
GB202104224D0 (en) Pharmaceutical composition
GB202018068D0 (en) Pharmaceutical composition
GB202010340D0 (en) Pharmaceutical composition
IL324773A (en) Pharmaceutical compositions
IL320961A (en) Milvexian pharmaceutical compositions
GB202313738D0 (en) Pharmaceutical compositions
GB202312055D0 (en) Pharmaceutical compositions
GB202217146D0 (en) New pharmaceutical compositions
GB202217150D0 (en) New pharmaceutical compositions
IL312071A (en) Pharmaceutical compositions
GB202316245D0 (en) Rapamycin-containing pharmaceutical composition
GB202013701D0 (en) Pharmaceutical compositions
GB202005742D0 (en) Novel pharmaceutical compositions
GB202510527D0 (en) Pharmaceutical compositions
GB202507034D0 (en) Pharmaceutical compositions
GB202507038D0 (en) Pharmaceutical compositions
GB202504959D0 (en) Pharmaceutical compositions
GB202504962D0 (en) Pharmaceutical compositions
GB202416866D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: IRL 790AB

Free format text: FORMER OWNERS: IPSEN BIOPHARM LIMITED;IRL 790 AB

AT Applications terminated before publication under section 16(1)